Data as of Q4 2025 (Dec 31, 2025)

FORTRESS BIOTECH, INC.

(FBIO)

Financial Statements · SEC EDGAR XBRL

Revenue
$63.3M
+9.7%
Net Income
$37.0M
+76.2%
EPS
$-0.07
+97.4%
Gross Margin
66.9%
Op. Income
-$70.2M
+36.4%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Selling General & Admin
Research & Development
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
$63.3M
$57.7M
$84.5M
$75.7M
$68.8M
$63.3M
$57.7M
$84.5M
$75.7M
$68.8M
$20.9M
$20.9M
$22.9M
$30.8M
$32.1M
$42.3M
$36.8M
$61.6M
$45.0M
$36.7M
$96.4M
$87.7M
$91.0M
$113.7M
$86.8M
-
-
$106.1M
$134.9M
$128.9M
-$70.2M
-$110.4M
-$142.3M
-$203.6M
-$188.5M
$36.7M
-$10.2M
-$11.3M
-$9.9M
$24.2M
-$33.5M
-$120.5M
-$153.6M
-$213.5M
-$164.4M
-$620K
$312K
$521K
$449K
$473K
$37.0M
$21.0M
$31.0M
-$86.6M
-$64.7M
$-0.07
$-2.69
$-8.47
$-15.97
$-0.79
$-0.07
$-2.69
$-8.47
$-15.97
$-0.79
-
-
-
-
81.7M